130 related articles for article (PubMed ID: 22726975)
1. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?
Sowa-Staszczak A; Chrzan R; Pach D; Stefańska A; Tomaszuk M; Buziak-Bereza M; Kołodziej M; Przybylik-Mazurek E; Hubalewska-Dydejczyk A
Clin Imaging; 2012; 36(4):360-4. PubMed ID: 22726975
[TBL] [Abstract][Full Text] [Related]
2. The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
Løitegård T; Berntzen DT; Thiis-Evensen E
Ann Nucl Med; 2019 Mar; 33(3):147-152. PubMed ID: 30406360
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
Sowa-Staszczak A; Pach D; Chrzan R; Trofimiuk M; Stefańska A; Tomaszuk M; Kołodziej M; Mikołajczak R; Pawlak D; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1669-74. PubMed ID: 21559978
[TBL] [Abstract][Full Text] [Related]
4. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
5. Radioembolization with
Braat AJAT; Ahmadzadehfar H; Kappadath SC; Stothers CL; Frilling A; Deroose CM; Flamen P; Brown DB; Sze DY; Mahvash A; Lam MGEH
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):246-253. PubMed ID: 31646375
[TBL] [Abstract][Full Text] [Related]
6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
7. Intense 18F-fluoride accumulation in liver metastases from a neuroendocrine tumor after peptide receptor radionuclide therapy.
Swiętaszczyk C; Prasad V; Baum RP
Clin Nucl Med; 2012 Apr; 37(4):e82-3. PubMed ID: 22391729
[No Abstract] [Full Text] [Related]
8. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging as in vivo molecular pathology for gastroenteropancreatic neuroendocrine tumors: implications for follow-up after therapy.
Krenning EP; Valkema R; Kwekkeboom DJ; de Herder WW; van Eijck CH; de Jong M; Pauwels S; Reubi JC
J Nucl Med; 2005 Jan; 46 Suppl 1():76S-82S. PubMed ID: 15653655
[TBL] [Abstract][Full Text] [Related]
10. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
[TBL] [Abstract][Full Text] [Related]
11. Semi-automatic 3D-volumetry of liver metastases from neuroendocrine tumors to improve combination therapy with 177Lu-DOTATOC and 90Y-DOTATOC.
Cieciera M; Kratochwil C; Moltz J; Kauczor HU; Holland Letz T; Choyke P; Mier W; Haberkorn U; Giesel FL
Diagn Interv Radiol; 2016; 22(3):201-6. PubMed ID: 27015320
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors: A Meta-analysis.
Saravana-Bawan B; Bajwa A; Paterson J; McEwan AJB; McMullen TPW
Clin Nucl Med; 2019 Sep; 44(9):719-727. PubMed ID: 31205149
[TBL] [Abstract][Full Text] [Related]
13. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
[TBL] [Abstract][Full Text] [Related]
14. Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 Trial.
Zhang J; Kulkarni HR; Singh A; Baum RP
Clin Nucl Med; 2019 Mar; 44(3):223-226. PubMed ID: 30672759
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.
Goncalves I; Burbury K; Michael M; Iravani A; Ravi Kumar AS; Akhurst T; Tiong IS; Blombery P; Hofman MS; Westerman D; Hicks RJ; Kong G
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1902-1910. PubMed ID: 31187162
[TBL] [Abstract][Full Text] [Related]
17. Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors.
Ladwa R; Wen Hong H; Wyld D; Pattison DA; Burge M
Clin Nucl Med; 2018 Mar; 43(3):186-187. PubMed ID: 29356741
[TBL] [Abstract][Full Text] [Related]
18. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
[TBL] [Abstract][Full Text] [Related]
19. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
20. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectable.
Barber TW; Hofman MS; Thomson BN; Hicks RJ
Eur J Surg Oncol; 2012 Jan; 38(1):64-71. PubMed ID: 21906907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]